Effects of a novel Nodal-targeting monoclonal antibody in melanoma

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Nodal is highly expressed in human malignancies, making it a potential therapeutic target.
• Targeting Nodal signaling may offer a new strategy for cancer treatment.

Purpose of the Study:

• To investigate the therapeutic potential of a novel monoclonal antibody (mAb), 3D1, against human Nodal.
• To evaluate the efficacy of 3D1 mAb in inhibiting cancer cell growth and signaling pathways.
• To explore the diagnostic utility of 3D1 mAb for Nodal detection in cancer patients.

Main Methods:

• In vitro studies using C8161 and A375SM melanoma cells treated with 3D1 mAb.
• In vivo studies using human melanoma xenografts in Nude mice treated with 3D1 mAb.
• Analysis of downstream signaling molecules (P-Smad2, P-ERK) and cell cycle markers (P-H3, CyclinB1, p27).
• Development of a 3D1-based ELISA for serum Nodal detection.

Main Results:

• 3D1 mAb treatment reduced anchorage-independent growth and vasculogenic network formation in melanoma cells.
• 3D1 mAb decreased Nodal expression and downstream signaling (P-Smad2, P-ERK) in cancer cells.
• In vivo studies showed reduced melanoma xenograft growth with diminished P-Smad2 expression.
• 3D1 mAb demonstrated comparable efficacy to dabrafenib in BRAF(V600E) mutated melanoma cells.
• A 3D1-based ELISA was developed for Nodal detection in patient serum.

Conclusions:

• The novel 3D1 mAb effectively targets Nodal signaling, inhibiting cancer cell proliferation and tumor growth.
• 3D1 mAb shows potential as a therapeutic agent for Nodal-expressing cancers.
• The 3D1-based ELISA may aid in selecting patients for Nodal-targeted therapies.